In Reply

Letters to the Editor Emphysematous Cystitis by Dr. med. Christopher Kloth, Prof. Dr. med. Jens Bedke, and Dr. med. Heike Preibsch in issue 27–28/2020

We thank our correspondents for pointing out the correct names of the active ingredients. These are, as mentioned, piperacillin from the group of ß-lactam antibiotics, in combination with tazobactam from the group of ß-lactamase inhibitors, and metronidazole from the group of nitroimidazoles.

We also wish to express our thanks for the valuable comments regarding the pathogenic entity and the antibiotic treatment spectrum. We have passed these on to our referring colleagues. The pathogen is correctly an Enterobacter cloacae complex.

We none the less think that the described case was extremely interesting, especially with regard to the impressive imaging result.

We are pleased that by responding to your comments we have had a more comprehensive option to discuss the symptoms of emphysematous cystitis and the importance of imaging in this setting.

DOI: 10.3238/arztebl.m2021.0062

Dr. med. Christopher Kloth

Klinik für Diagnostische und Interventionelle Radiologie

Universitätsklinikum Ulm

Dr. med. Heike Preibsch

Abteilung für Diagnostische und Interventionelle Radiologie, Universitätsklinik Tübingen

Conflict of interest statement

The authors of both contributions declare that no conflict of interest exists.

References

1. Kloth C, Bedke J, Preibsch H: Emphysematous cystitis. Dtsch Arztebl Int 2020; 117: 487